Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

AATD is a genetic disorder most commonly caused by a single missense mutation (G-to-A) in the SERPINA1 gene. Affected adults experience pulmonary emphysema and/or hepatic cirrhosis, as well as end organ manifestations. KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro's proprietary RNA editing platform, Oligonucleotide Promoted Editing of RNA (OPERA). KRRO-110, a potential best-in- class compound based on preclinical data, is designed to co-opt an endogenous enzyme, Adenosine De ...